Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

Authors: Tholouli, Eleni1; Liakopoulou, Effie2; Greenfield, Hayley M.1; Shaw, Bronwen E.3; Tauro, Sudhir4; Byrne, Jennifer L.3; Dennis, Mike2; Burthem, John1; Lucas, Guy S.1; Craddock, Charles4; Russell, Nigel H.3; Liu Yin, John A.1

Source: British Journal of Haematology, Volume 142, Number 2, July 2008 , pp. 318-320(3)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: alemtuzumab; acute myeloid leukaemia; poor risk myelodysplasia; reduced intensity conditioning; stem cell transplant

Document Type: Correspondence

DOI: 10.1111/j.1365-2141.2008.07184.x

Affiliations: 1: University Department of Haematology, Manchester Royal Infirmary, Manchester 2: Department of Haematology, Christie Hospital, Manchester 3: Department of Haematology, City Hospital, Nottingham 4: Department of Haematology, University Hospital Birmingham, Birmingham, UK., Email: john.yin@cmmc.nhs.uk

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A